tiprankstipranks
Advertisement
Advertisement

MLLCF Stock Latest News

Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
The FlyMolecular Partners to hold trial-in-progress presentations on Phase 1/2a study
3d ago
MOLN
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
PremiumRatings
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
22d ago
MOLN
Molecular Partners publishes MP0317 clinical data in Nature Cancer
PremiumThe Fly
Molecular Partners publishes MP0317 clinical data in Nature Cancer
1M ago
MOLN
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
PremiumRatings
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
1M ago
MOLN
Molecular Partners announces presentation of preclinical data at AACR
PremiumThe Fly
Molecular Partners announces presentation of preclinical data at AACR
2M ago
MOLN
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
PremiumRatingsMolecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
3M ago
MOLN
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
Premium
Ratings
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
3M ago
MOLN
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
Premium
Ratings
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
3M ago
MOLN
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
PremiumRatings
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
3M ago
MOLN
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
PremiumThe Fly
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
3M ago
MOLN
Molecular Partners presents first imaging, dosimetry data of MP0712
PremiumThe Fly
Molecular Partners presents first imaging, dosimetry data of MP0712
4M ago
MOLN
Molecular Partners initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Molecular Partners initiated with a Buy at H.C. Wainwright
4M ago
MOLN
Molecular Partners provided update on latest progress, 2026 milestones
PremiumThe FlyMolecular Partners provided update on latest progress, 2026 milestones
5M ago
MOLN
Molecular Partners Advances DLL3 Radioligand Program With New Phase 1/2a Cancer Trial
Premium
Company Announcements
Molecular Partners Advances DLL3 Radioligand Program With New Phase 1/2a Cancer Trial
5M ago
MLLCF
Molecular Partners forms Scientific Advisory Board
Premium
The Fly
Molecular Partners forms Scientific Advisory Board
6M ago
MOLN
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
PremiumRatings
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
6M ago
MOLN
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
PremiumThe Fly
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
6M ago
MOLN
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
PremiumThe Fly
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
6M ago
MOLN
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
PremiumThe Fly
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
6M ago
MOLN
Buy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements
PremiumRatingsBuy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements
7M ago
MOLN
Molecular Partners presents new MP0712 data
Premium
The Fly
Molecular Partners presents new MP0712 data
7M ago
MOLN
Molecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating
Premium
Ratings
Molecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating
7M ago
MOLN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >